دورية أكاديمية
Prebiotic proanthocyanidins inhibit bile reflux-induced esophageal adenocarcinoma through reshaping the gut microbiome and esophageal metabolome.
العنوان: | Prebiotic proanthocyanidins inhibit bile reflux-induced esophageal adenocarcinoma through reshaping the gut microbiome and esophageal metabolome. |
---|---|
المؤلفون: | Weh KM; Department of Surgery, Section of Thoracic Surgery, and.; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA., Howard CL; Department of Surgery, Section of Thoracic Surgery, and.; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA., Zhang Y; Department of Surgery, Section of Thoracic Surgery, and.; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA., Tripp BA; Department of Electrical and Computer Engineering, and., Clarke JL; Department of Statistics, Department of Food Science Technology, Quantitative Life Sciences Initiative, University of Nebraska-Lincoln, Lincoln, Nebraska, USA., Howell AB; Marucci Center for Blueberry and Cranberry Research, Rutgers University, Chatsworth, New Jersey, USA., Rubenstein JH; Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.; LTC Charles S. Kettles Veterans Affairs Medical Center, Ann Arbor, Michigan, USA., Abrams JA; Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA., Westerhoff M; Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA., Kresty LA; Department of Surgery, Section of Thoracic Surgery, and.; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA. |
المصدر: | JCI insight [JCI Insight] 2024 Feb 08; Vol. 9 (6). Date of Electronic Publication: 2024 Feb 08. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Ann Arbor, Michigan : American Society for Clinical Investigation, [2016]- |
مواضيع طبية MeSH: | Proanthocyanidins*/pharmacology , Proanthocyanidins*/therapeutic use , Proanthocyanidins*/metabolism , Gastrointestinal Microbiome*/physiology , Bile Reflux* , Adenocarcinoma*/genetics , Gastroesophageal Reflux*/drug therapy , Gastroesophageal Reflux*/genetics , Esophageal Neoplasms*, Humans ; Rats ; Animals ; Dysbiosis/drug therapy ; Rats, Sprague-Dawley ; Inflammation/drug therapy ; Metabolome |
مستخلص: | The gut and local esophageal microbiome progressively shift from healthy commensal bacteria to inflammation-linked pathogenic bacteria in patients with gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma (EAC). However, mechanisms by which microbial communities and metabolites contribute to reflux-driven EAC remain incompletely understood and challenging to target. Herein, we utilized a rat reflux-induced EAC model to investigate targeting the gut microbiome-esophageal metabolome axis with cranberry proanthocyanidins (C-PAC) to inhibit EAC progression. Sprague-Dawley rats, with or without reflux induction, received water or C-PAC ad libitum (700 μg/rat/day) for 25 or 40 weeks. C-PAC exerted prebiotic activity abrogating reflux-induced dysbiosis and mitigating bile acid metabolism and transport, culminating in significant inhibition of EAC through TLR/NF-κB/TP53 signaling cascades. At the species level, C-PAC mitigated reflux-induced pathogenic bacteria (Streptococcus parasanguinis, Escherichia coli, and Proteus mirabilis). C-PAC specifically reversed reflux-induced bacterial, inflammatory, and immune-implicated proteins and genes, including Ccl4, Cd14, Crp, Cxcl1, Il6, Il1b, Lbp, Lcn2, Myd88, Nfkb1, Tlr2, and Tlr4, aligning with changes in human EAC progression, as confirmed through public databases. C-PAC is a safe, promising dietary constituent that may be utilized alone or potentially as an adjuvant to current therapies to prevent EAC progression through ameliorating reflux-induced dysbiosis, inflammation, and cellular damage. |
التعليقات: | Update of: bioRxiv. 2023 Aug 23;:. (PMID: 37662411) |
References: | Int J Mol Sci. 2018 Mar 15;19(3):. (PMID: 29543757) JCI Insight. 2020 Jul 23;5(14):. (PMID: 32699194) Eur Rev Med Pharmacol Sci. 2017 Jan;21(2):389-393. (PMID: 28165546) Front Med (Lausanne). 2017 Oct 03;4:163. (PMID: 29043249) Phytother Res. 2012 Sep;26(9):1371-4. (PMID: 22294419) Signal Transduct Target Ther. 2020 Jun 10;5(1):90. (PMID: 32532965) Genome Med. 2021 Aug 19;13(1):133. (PMID: 34412659) Anal Bioanal Chem. 2013 May;405(13):4385-95. (PMID: 23397091) Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):6410-6415. (PMID: 29866855) Food Funct. 2019 Dec 11;10(12):7645-7652. (PMID: 31702761) Gigascience. 2012 Jul 12;1(1):7. (PMID: 23587224) Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1687-1693. (PMID: 31466948) J Invest Dermatol. 2011 Apr;131(4):932-43. (PMID: 21191420) Environ Microbiol. 2016 Jun;18(6):2039-51. (PMID: 26914164) Br J Nutr. 2020 Sep 28;124(6):577-585. (PMID: 32301407) Cancer Epidemiol. 2018 Apr;53:172-177. (PMID: 29477057) Oncotarget. 2015 Oct 20;6(32):33438-55. (PMID: 26378019) Oncol Rep. 2015 Sep;34(3):1424-30. (PMID: 26133772) Best Pract Res Clin Gastroenterol. 2013 Jun;27(3):401-14. (PMID: 23998978) Clin Cancer Res. 2016 Nov 15;22(22):5574-5581. (PMID: 27769987) Lab Invest. 2004 Jun;84(6):753-65. (PMID: 15094711) Clin Cancer Res. 2012 Apr 15;18(8):2138-44. (PMID: 22344232) Pediatr Dent. 2019 Jan 15;41(1):56-62. (PMID: 30803479) Cell Death Discov. 2021 Mar 29;7(1):62. (PMID: 33782397) Mol Med. 2021 Nov 5;27(1):144. (PMID: 34740314) Biomed Opt Express. 2016 Mar 21;7(4):1400-14. (PMID: 27446664) Gut. 2023 Mar;72(3):421-432. (PMID: 35750470) Carcinogenesis. 1999 Sep;20(9):1801-8. (PMID: 10469627) Aliment Pharmacol Ther. 2018 Aug;48(4):469-477. (PMID: 29956826) Curr Treat Options Gastroenterol. 2018 Mar;16(1):72-85. (PMID: 29350339) JAMA Intern Med. 2016 Feb;176(2):238-46. (PMID: 26752337) Anticancer Res. 2022 Jun;42(6):2813-2818. (PMID: 35641301) J Antimicrob Chemother. 2014 Feb;69(2):428-36. (PMID: 24114570) Am J Clin Nutr. 2016 Jun;103(6):1434-42. (PMID: 27251185) Nature. 2020 Oct;586(7827):133-138. (PMID: 32728212) J Nutr Biochem. 2018 Dec;62:76-86. (PMID: 30269035) Nutrients. 2020 Jan 02;12(1):. (PMID: 31906573) Pharmacogenomics J. 2010 Aug;10(4):310-23. (PMID: 20676069) Cancer Metastasis Rev. 2022 Jun;41(2):281-299. (PMID: 35511379) J Thorac Cardiovasc Surg. 2011 Feb;141(2):469-75, 475.e1-4. (PMID: 20880550) Int J Toxicol. 2006 Jul-Aug;25(4):231-59. (PMID: 16815813) J Gastroenterol. 2014 Jul;49(7):1121-34. (PMID: 23955118) Gut. 2015 Jun;64(6):872-83. (PMID: 25080446) Gastroenterology. 2019 Apr;156(5):1404-1415. (PMID: 30578782) Mol Ther Nucleic Acids. 2022 Aug 17;29:749-768. (PMID: 36090744) Drug Deliv Transl Res. 2021 Jun;11(3):1144-1155. (PMID: 32783154) Gut. 2016 May;65(5):740-8. (PMID: 26657899) Gut. 2018 Jul;67(7):1369-1370. (PMID: 28993417) Mol Carcinog. 2016 Nov;55(11):1876-1885. (PMID: 27696537) Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Dec;160(4):559-565. (PMID: 27833172) PLoS One. 2015 May 27;10(5):e0127287. (PMID: 26016641) Nutrients. 2022 Jul 20;14(14):. (PMID: 35889921) Int J Cancer. 2022 Nov 15;151(10):1703-1716. (PMID: 35751398) Antioxidants (Basel). 2016 Aug 18;5(3):. (PMID: 27548236) Mol Carcinog. 2022 Mar;61(3):281-287. (PMID: 34758158) Nutrients. 2019 Nov 22;11(12):. (PMID: 31766592) Am J Physiol Endocrinol Metab. 2018 Apr 1;314(4):E334-E352. (PMID: 28874357) Ther Adv Drug Saf. 2013 Jun;4(3):125-33. (PMID: 25083257) J Gastroenterol Hepatol. 2021 Apr;36(4):927-935. (PMID: 32783238) Nat Genet. 2015 Sep;47(9):1047-55. (PMID: 26192918) Mol Nutr Food Res. 2016 Oct;60(10):2130-2140. (PMID: 27242317) BMC Infect Dis. 2010 Apr 14;10:94. (PMID: 20398248) J Immunol. 2018 Jan 15;200(2):758-767. (PMID: 29196459) Nat Rev Gastroenterol Hepatol. 2021 Jun;18(6):432-443. (PMID: 33603224) Cell Rep. 2020 Feb 18;30(7):2083-2093.e5. (PMID: 32075732) PLoS One. 2019 Feb 8;14(2):e0212045. (PMID: 30735540) Gut. 2010 Dec;59(12):1606-16. (PMID: 20876775) JCI Insight. 2021 Jan 11;6(1):. (PMID: 33290281) Food Funct. 2015 Apr;6(4):1212-7. (PMID: 25723356) Gastroenterol Clin North Am. 2015 Jun;44(2):203-31. (PMID: 26021191) Nat Biotechnol. 2013 Sep;31(9):814-21. (PMID: 23975157) Nucleic Acids Res. 2000 Jan 1;28(1):27-30. (PMID: 10592173) Nutrients. 2017 Mar 11;9(3):. (PMID: 28287476) Nutrients. 2022 Feb 24;14(5):. (PMID: 35267943) Cancer Res. 2010 Nov 15;70(22):9129-36. (PMID: 20884633) OMICS. 2018 Feb;22(2):145-153. (PMID: 28618237) Nat Genet. 2019 Mar;51(3):506-516. (PMID: 30718927) BMC Cancer. 2013 Mar 21;13:137. (PMID: 23514407) Front Microbiol. 2022 Jan 14;12:791274. (PMID: 35126331) Clin Gastroenterol Hepatol. 2021 Nov;19(11):2284-2292.e2. (PMID: 32835843) J Gastrointest Surg. 2004 May-Jun;8(4):413-22. (PMID: 15120365) Gut. 2014 Aug;63(8):1229-37. (PMID: 24221456) Am J Physiol Gastrointest Liver Physiol. 2021 Sep 1;321(3):G335-G343. (PMID: 34405732) Microorganisms. 2021 Aug 10;9(8):. (PMID: 34442780) Microorganisms. 2021 Aug 18;9(8):. (PMID: 34442842) Microbiologyopen. 2015 Jun;4(3):465-74. (PMID: 25771812) Subcell Biochem. 2014;85:187-97. (PMID: 25201195) Nutrition. 2011 Feb;27(2):182-7. (PMID: 20538426) |
معلومات مُعتمدة: | R01 CA158319 United States CA NCI NIH HHS; R01 CA272898 United States CA NCI NIH HHS; U54 CA163059 United States CA NCI NIH HHS; R01 CA238433 United States CA NCI NIH HHS; R01 CA255298 United States CA NCI NIH HHS; U54 CA163004 United States CA NCI NIH HHS |
فهرسة مساهمة: | Keywords: Cancer; Gastroenterology; NF-kappaB; Oncology; Transport |
المشرفين على المادة: | 0 (Proanthocyanidins) |
SCR Disease Name: | Adenocarcinoma Of Esophagus |
تواريخ الأحداث: | Date Created: 20240208 Date Completed: 20240325 Latest Revision: 20240504 |
رمز التحديث: | 20240504 |
مُعرف محوري في PubMed: | PMC11063939 |
DOI: | 10.1172/jci.insight.168112 |
PMID: | 38329812 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2379-3708 |
---|---|
DOI: | 10.1172/jci.insight.168112 |